Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
- 1 May 2002
- journal article
- on the-market
- Published by Springer Nature in Nature Medicine
- Vol. 8 (5) , 527-531
- https://doi.org/10.1038/nm0502-527
Abstract
Noninvasive methods are needed to study the kinetic properties of viruses in living organisms. Oncolytic viruses are used increasingly for cancer therapy but there is currently no satisfactory way to measure efficiency of tumor transduction, changing levels of viral gene expression or the timing of virus elimination. We therefore generated trackable oncolytic measles viruses expressing inert (nonimmunogenic, nonfunctional and accurately measurable) soluble marker peptides. The marker peptides did not compromise virus replication. Ex vivo and in vivo kinetics of the trackable viruses could be easily followed by measuring the concentrations of virally encoded marker peptides in culture supernatant or in serum. When mice bearing human tumor xenografts were challenged with the trackable viruses, distinct kinetic profiles of marker-gene expression could be correlated with distinct therapeutic outcomes. Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Quantitative imaging of gene induction in living animalsGene Therapy, 2001
- Replication-selective virotherapy for cancer: Biological principles, risk management and future directionsNature Medicine, 2001
- Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancerNature Medicine, 2001
- Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck CancerJournal of Clinical Oncology, 2001
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Reovirus as a novel oncolytic agentJournal of Clinical Investigation, 2000
- Replication-selective adenoviruses as oncolytic agentsJournal of Clinical Investigation, 2000
- Conditionally replicating herpes vectors for cancer therapyJournal of Clinical Investigation, 2000
- Disappearance Curves for Tumor Markers after Resection of Intrathoracic MalignanciesThe International Journal of Biological Markers, 1999
- Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus TherapyJNCI Journal of the National Cancer Institute, 1994